New tendencies in the construction of subunit vaccines;Nowe tendencje w konstrukcji szczepionek podjednostkowych

Postepy Mikrobiologii

Volumn 45, Issue 2, 2006, Pages 119-134

  Wyszyńska, Agnieszka ^a   Jagusztyn Krynicka, Elzbieta Katarzyna ^a  

^a UNIVERSITY OF WARSAW   (Poland)

Author keywords

Adjuvant; Antigen; Probiotics; Subunit vaccines

Indexed keywords

SUBUNIT VACCINE;

ANTIGEN EXPRESSION; BIOINFORMATICS; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; FREEZING; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; LACTIC ACID BACTERIUM; LIFE EXPECTANCY; MUCOSAL IMMUNITY; NONHUMAN; PATHOGENESIS; POLIOMYELITIS; QUALITY OF LIFE; REVIEW; SMALLPOX; VACCINE PRODUCTION;

BACTERIA (MICROORGANISMS); VARIOLA VIRUS;

EID: 33745934268     PISSN: 00794252     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Akira S., Hemmi H.: Recognition of pathogen-associated molecular patterns by TLR family. Immunol. Lett. 85, 85-95 (2003)
2. Ang S., Lee C.Z., Peck K., Sindici M., Matrubutham U., Gleeson M.A., Wang J.T.: Acid-induced gene expression in Helicobacter pylori: study in genomic scale by microarray. Infect. Immun. 69, 1679-1686 (2001)
3. Arakawa T., Chong D.K., Langridge W.H.: Efficacy of a food plant-based oral cholera toxin B subunit vaccine. Nat. Biotechnol. 16, 292-297 (1998)
4. Baqar S., Bourgeois A.L., Schultheiss P.J., Walker R.I., Rollins D.M., Haberberger R.L., Pavlovskis O.R.: Safety and immunogenicity of a prototype oral whole-cell killed Campylobacter vaccine administered with a mucosal adjuvant in non-human primates. Vaccine, 13, 22-28 (1995)
5. Bermudez-Humaran L.G., Langella P., Cortes-Perez N.G., Gruss A., Tamez-Guerra R.S., Oliveira S.C., Saucedo-Cardenas O., Montes de Oca-Luna R., Le Loir Y.: Intranasal immunization with recombinant Lactococcus lactis secreting murine interleukin-12 enhances antigen-specific Th1 cytokine production. Infect. Immun. 71, 1887-1896 (2003)
6. Bohn E., Autenrieth I.B. i wsp.: Gene expression patterns of epithelial cells modulated by pathogenicity factors of Yersinia enterocolitica. Cell Microbiol. 6, 129-141 (2004)
7. Bolotin A., Wincker P., Mauger S., Jaillon O., Malarme K., Weissenbach J., Ehrlich S.D., Sorokin A.: The complete genome sequence of the lactic acid bacterium Lactococcus lactis ssp. lactis IL1403. Genome Res. 11, 731-753 (2001)
8. Braun M.C., He J., Wu C.Y., Kelsall B.L.: Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor b1 and b2 chain expression. J. Exp. Med. 189, 541-552 (1999)
9. Bullifent H.L., Griffin K.F., Jones S.M., Yates A., Harrington L., Titball R.W.: Antibody responses to Yersinia pestis F1-antigen expressed in Salmonella typhimurium aroA from in vivo-inducible promoters. Vaccine, 18, 2668-2676 (2000)
10. Carneiro L.A., Travassos L.H., Philpott D.J.: Innate immune recognition of microbes through Nod1 and Nod2: implications for disease. Microbes Infect. 6, 609-616 (2004)
11. Chatfield S., Dougan G., Attenuated Salmonella as a live vector for expression of foreign antigens. (Expressing bacterial antigens). (w) New Generation Vaccines, red. M.M. Levine, G.C. Woodrow, J.B. Kaper, G.S. Cobon, Marcel Dekker, Inc. New York, Basel and Honk Kong, 1997, s. 331-341.
12. Chatfield S.N., Charles I.G., Makoff A.J., Oxer M.D., Dougan G., Pickard D., Slater D., Fairweather N.F.: Use of the nirB promoter to direct the stable expression of heterologous antigens in Salmonella oral vaccine strains: development of a single-dose oral tetanus vaccine. Biotechnology, 10, 888-892 (1992)
13. Chen H.: Recent advances in mucosal vaccine development. J. Control. Release. 67, 117-128 (2000)
14. Chikwamba R., Cunnick J., Hathaway D., McMurray J., Mason H., Wang K.: A functional antigen in a practical crop: LT-B producing maize protects mice against Escherichia coli heat labile enterotoxin (LT) and cholera toxin (CT). Transgenic Res. 11, 479-493 (2002)
15. Chu R.S., Targoni O., Krieg A.M., Lehmann P.V., Harding C.V.: CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 186, 1623-1631 (1997)
16. Cox J.C., Coulter A.R.: Adjuvants - a classification and review of their modes of action. Vaccine, 15, 248-256 (1997)
17. Curtiss R.I., Cardineau C.A.: Oral immunisation by transgenic plants. World Patent Application 1990 WO 90/02484].
18. Curtiss R., 3rd, Nakayama K., Kelly S.M.: Recombinant avirulent Salmonella vaccine strains with stable maintenance and high level expression of cloned genes in vivo. Immunol. Invest. 18, 583-596 (1989)
19. Daniell H., Lee S.B., Panchal T., Wiebe P.O.: Expression of the native cholera toxin B subunit gene and assembly as functional oligomers in transgenic tobacco chloroplasts. J. Mol. Biol. 311, 1001-1009 (2001)
20. Darji A., Guzman C.A., Gerstel B., Wachholz P., Timmis K.N., Wehland J., Chakraborty T., Weiss S.: Oral somatic transgene vaccination using attenuated S. typhimurium. Cell, 91, 765-775 (1997)
21. Davis H.L., Weeratna R., Waldschmidt T.J., Tygrett L., Schorr J., Krieg A.M., Weeranta R.: CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160, 870-876 (1998)
22. Dertzbaugh M.T.: Genetically engineered vaccines: an overview. Plasmid, 39, 100-113 (1998)
23. Dittmer U., Olbrich A.R.: Treatment of infectious diseases with immunostimulatory oligodeoxynucleotides containing CpG motifs. Curr. Opin. Microbiol. 6, 472-477 (2003)
24. Douce G., Fontana M., Pizza M., Rappuoli R., Dougan G.: Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect. Immun. 65, 2821-2828 (1997)
25. Douce G., Giuliani M.M., Giannelli V., Pizza M.G., Rappuoli R., Dougan G.: Mucosal immunogenicity of genetically detoxified derivatives of heat labile toxin from Escherichia coli. Vaccine, 16, 1065-1073 (1998)
26. Eko F.O., Lubitz W., McMillan L., Ramey K., Moore T.T., Ananaba G.A., Lyn D., Black C.M., Igietseme J.U.: Recombinant Vibrio cholerae ghosts as a delivery vehicle for vaccinating against Chlamydia trachomatis. Vaccine, 21, 1694-1703 (2003)
27. Enouf V., Langella P., Commissaire J., Cohen J., Corthier G.: Bovine rotavirus nonstructural protein 4 produced by Lactococcus lactis is antigenic and immunogenic. Appl. Environ. Microbiol. 67, 1423-1428 (2001)
28. Everest P., Frankel G., Li J., Lund P., Chatfield S., Dougan G.: Expression of LacZ from the htrA, nirB and groE promoters in a Salmonella vaccine strain: influence of growth in mammalian cells. FEMS Microbiol. Lett. 126, 97-101 (1995)
29. Galen J.E., Nair J., Wang J.Y., Wasserman S.S., Tanner M.K., Sztein M.B., Levine M.M.: Optimization of plasmid maintenance in the attenuated live vector vaccine strain Salmonella typhi CVD 908-htrA. Infect. Immun. 67, 6424-6433 (1999)
30. Gallichan W.S., Woolstencroft R.N., Guarasci T., McCluskie M.J., Davis H.L., Rosenthal K.L.: Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J. Immunol. 166, 3451-3457 (2001)
31. Germanier R., Fuer E.: Isolation and characterization of GalE mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. J. Infect. Dis. 131, 553-558 (1975)
32. Ghiara P., Del Giudice G. i wsp.: Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection. Infect. Immun. 65, 4996-5002 (1997)
33. Gluck U., Gebbers J.O., Gluck R.: Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers. J. Virol. 73, 7780-7786 (1999)
34. Gonzalez C.R., Noriega F.R., Huerta S., Santiago A., Vega M., Paniagua J., Ortiz-Navarrete V., Isibasi A., Levine M.M.: Immunogenicity of a Salmonella typhi CVD 908 candidate vaccine strain expressing the major surface protein gp63 of Leishmania mexicana mexicana. Vaccine, 16, 1043-1052 (1998)
35. Grangette C., Muller-Alouf H., Geoffroy M., Goudercourt D., Turneer M., Mercenier A.: Protection against tetanus toxin after intragastric administration of two recombinant lactic acid bacteria: impact of strain viability and in vivo persistence. Vaccine, 20, 3304-3309 (2002)
36. Grangette C., Muller-Alouf H., Goudercourt D., Geoffroy M.C., Turneer M., Mercenier A.: Mucosal immune responses and protection against tetanus toxin after intranasal immunization with recombinant Lactobacillus plantarum. Infect. Immun. 69, 1547-1553 (2001)
37. Haan L., Verweij W.R., Holtrop M., Brands R., van Scharrenburg G.J., Palache A.M., Agsteribbe E., Wilschut J.: Nasal or intramuscular immunization of mice with influenza subunit antigen and the B subunit of Escherichia coli heat-labile toxin induces IgA- or IgG-mediated protective mucosal immunity. Vaccine, 19, 2898-2907 (2001)
38. Hahn H.P., Hess C., Gabelsberger J., Domdey H., von Specht B.U.: A Salmonella typhimurium strain genetically engineered to secrete effectively a bioactive human interleukin (ML)-6 via the Escherichia coli hemolysin secretion apparatus. FEMS Immunol. Med. Microbiol. 20, 111-119 (1998)
39. Hallet B.: Playing Dr Jekyll and Mr Hyde: combined mechanisms of phase variation in bacteria. Curr. Opin. Microbiol. 4, 570-581 (2001)
40. Hensel A., Huter V., Katinger A., Raza P., Strnistschie C., Roesler U., Brand E., Lubitz W.: Intramuscular immunization with genetically inactivated (ghosts) Actinobacillus pleuropneumoniae serotype 9 protects pigs against homologous aerosol challenge and prevents carrier state. Vaccine, 18, 2945-2955 (2000)
41. Horner A.A., Raz E.: Immunostimulatory sequence oligodeoxynucleotide: A novel mucosal adjuvant. Clin. Immunol. 95, S19-29 (2000)
42. Huter V., Hensel A., Brand E., Lubitz W.: Improved protection against lung colonization by Actinobacillus pleuropneumoniae ghosts: characterization of a genetically inactivated vaccine. J. Biotechnol. 83, 161-172 (2000)
43. Ichikawa J.K., Norris A., Bangera M.G., Geiss G.K., van't Wout A.B., Bumgarner R.E., Lory S.: Interaction of pseudomonas aerugmosa with epithelial cells: identification of differentially regulated genes by expression microarray analysis of human cDNAs. Proc. Natl. Acad. Sci. USA, 97, 9659-9664 (2000)
44. Jalava K., Eko F.O., Riedmann E., Lubitz W.: Bacterial ghosts as carrier and targeting systems for mucosal antigen delivery. Expert. Rev. Vaccines, 2, 45-51 (2003)
45. Kang H.Y., Srinivasan J., Curtiss R., 3rd: Immune responses to recombinant pneumococcal PspA antigen delivered by live attenuated Salmonella enterica sv. Typhimurium vaccine. Infect. Immun. 70, 1739-1749 (2002)
46. Klinman D.M., Takeshita F., Gursel I., Leifer C., Ishii K.J., Verthelyi D., Gursel M.: CpG DNA: recognition by and activation of monocytes. Microbes Infect. 4, 897-901 (2002)
47. Krieg A.M.: The role of CpG motifs in innate immunity. Curr Opin Immunol, 12, 35-43 (2000)
48. Lax A.J., Thomas W.: How bacteria could cause cancer: one step at a time. Trends Microbiol. 10, 293-299 (2002)
49. Lee M.H., Roussel Y., Wilks M., Tabaqchali S.: Expression of Helicobacter pylori urease subunit B gene in Lactococcus lactis MG1363 and its use as a vaccine delivery system against H. pylori infection in mice. Vaccine, 19, 3927-3935 (2001)
50. Levine M.M., Kaper J.B., Herrington D., Ketley J., Losonsky G., Tacket C.O., Tall B., Cryz S.: Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet, 2, 467-470 (1988)
51. Logan R.P.: Helicobacter pylori and gastric cancer. Lancet, 344, 1078-1079 (1994)
52. Lycke N.: The mechanism of cholera toxin adjuvanticity. Res. Immunol. 148, 504-520 (1997)
53. Lycke N., Tsuji T., Holmgren J.: The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur. J. Immunol. 22, 2277-2281 (1992)
54. Marshall D.G., Haque A., Fowler R., Del Guidice G., Dorman C.J., Dougan G., Bowe F.: Use of the stationary phase inducible promoters, spv and dps, to drive heterologous antigen expression in Salmonella vaccine strains. Vaccine, 18, 1298-1306 (2000)
55. Mason H.S., Ball J.M., Shi J.J., Jiang X., Estes M.K., Arntzen C.J.: Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. Proc. Natl. Acad. Sci. USA, 93, 5335-5340 (1996)
56. Mason H.S., Haq T.A., Clements J.D., Arntzen C.J.: Edible vaccine protects mice against Escherichia coli heat-labile enterotoxin (LT): potatoes expressing a synthetic LT-B gene. Vaccine, 16, 1336-1343 (1998)
57. McCluskie M.J., Davis H.L.: CpG DNA as mucosal adjuvant. Vaccine 18, 231-237 (1999)
58. McCluskie M.J., Weeratna R.D., Krieg A.M., Davis H.L.: CpG DNA is an effective oral adjuvant to protein antigens in mice. Vaccine, 19, 950-957 (2000)
59. McNeill H.V., Sinha K.A., Hormaeche C.E., Lee J.J., Khan C.M.: Development of a nonantibiotic dominant marker for positively selecting expression plasmids in multivalent Salmonella vaccines. Appl. Environ. Microbiol. 66, 1216-1219 (2000)
60. Medzhitov R., Preston-Hurlburt P., Janeway C.A., Jr.: A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature, 388, 394-397 (1997)
61. Miklos G.L., Maleszka R.: Microarray reality checks in the context of a complex disease. Nat. Biotechnol. 22, 615-621 (2004)
62. Millar D.G., Hirst T.R., Snider D.P.: Escherichia coli heat-labile enterotoxin B subunit is a more potent mucosal adjuvant than its closely related homologue, the B subunit of cholera toxin. Infect. Immun. 69, 3476-3482 (2001)
63. Modelska A., Dietzschold B., Sleysh N., Fu Z.F., Steplewski K., Hooper D.C., Koprowski H., Yusibov V.: Immunization against rabies with plant-derived antigen. Proc. Natl. Acad. Sci. USA, 95, 2481-2485 (1998)
64. Moldoveanu Z., Love-Homan L., Huang W., Krieg A.: CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 16, 1216-1224 (1998)
65. Mora M., Veggi D., Santini L., Pizza M., Rappuoli R.: Reverse vaccinology. Drug. Discov. Today, 8, 459-464 (2003)
66. Nashar T.O., Hirst T.R., Williams N.A.: Modulation of B-cell activation by the B subunit of Escherichia coli enterotoxin: receptor interaction up-regulates MHC class II, B7, CD40, CD25 and ICAM-1. Immunology, 91, 572-578 (1997)
67. Nouaille S., Ribeiro L.A., Miyoshi A., Pontes D., Le Loir Y., Oliveira S.C., Langella P., Azevedo V.: Heterologous protein production and delivery systems for Lactococcus lactis. Genet. Mol. Res. 2, 102-111 (2003)
68. Orr N., Galen J.E., Levine M.M.: Novel use of anaerobically induced promoter, dmsA, for controlled expression of fragment C of tetanus toxin in live attenuated Salmonella enterica sv. Typhi strain CVD 908-htrA. Vaccine, 19, 1694-1700 (2001)
69. Park E.J., Chang J.H., Kim J.S., Yum J.S., Chung S.I.: The mucosal adjuvanticity of two nontoxic mutants of Escherichia coli heat-labile enterotoxin varies with immunization routes. Exp. Mol. Med. 32, 72-78 (2000)
70. Parkhill J., Barrell B.G. i wsp.: The genome sequence of the food-borne pathogen Campylobacter jejuni reveals hypervariable sequences. Nature, 403, 665-668 (2000)
71. Petrovska L., Lopes L., Simmons C.P., Pizza M., Dougan G., Chain B.M.: Modulation of dendritic cell endocytosis and antigen processing pathways by Escherichia coli heat-labile enterotoxin and mutant derivatives. Vaccine, 21, 1445-1454 (2003)
72. Rappuoli R.: Reverse vaccinology. Curr. Opin. Microbiol. 3, 445-450 (2000)
73. Rappuoli R., Covacci A.: Reverse vaccinology and genomics. Science, 302, 602 (2003)
74. Rappuoli R., Pizza M., Douce G., Dougan G.: Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol. Today, 20, 493-500 (1999)
75. Richards C.M., Aman A.T., Hirst T.R., Hill T.J., Williams N.A.: Protective mucosal immunity to ocular herpes simplex virus type 1 infection in mice by using Escherichia coli heat-labile enterotoxin B subunit as an adjuvant. J. Virol. 75, 1664-1671 (2001)
76. Rollwagen F.M., Pacheco N.D., Clements J.D., Pavlovskis O., Rollins D.M., Walker R.I.: Killed Campylobacter elicits immune response and protection when administered with an oral adjuvant. Vaccine, 11, 1316-1320 (1993)
77. Ruddock L.W., Ruston S.P., Kelly S.M., Price N.C., Freedman R.B., Hirst T.R.: Kinetics of acid-mediated disassembly of the B subunit pentamer of Escherichia coli heat-labile enterotoxin. Molecular basis of pH stability. J. Biol. Chem. 270, 29953-29958 (1995)
78. Sala F., Manuela Rigano M., Barbante A., Basso B., Walmsley A.M., Castiglione S.: Vaccine antigen production in transgenic plants: strategies, gene constructs and perspectives. Vaccine, 21, 803-808 (2003)
79. Saunders N.J., Peden J.F., Hood D.W., Moxon E.R.: Simple sequence repeats in the Helicobacter pylori genome. Mol. Microbiol. 27, 1091-1098 (1998)
80. Servin A.L., Coconnier M.H.: Adhesion of probiotic strains to the intestinal mucosa and interaction with pathogens. Best Pract. Res. Clin. Gastroenterol. 17, 741-754 (2003)
81. Staats H.F., Bradney C.P., Gwinn W.M., Jackson S.S., Sempowski G.D., Liao H.X., Letvin N.L., Haynes B.F.: Cytokine requirements for induction of systemic and mucosal CTL after nasal immunization. J. Immunol. 167, 5386-5394 (2001)
82. Staats H.F., Ennis F.A., Jr.: IL-1 is an effective adjuvant for mucosal and systemic immune responses when coadministered with protein immunogens. J Immunol, 162, 6141-6147 (1999)
83. Steidler L.: Microbiological and immunological strategies for treatment of inflammatory bowel disease. Microbes Infect. 3, 1157-1166 (2001)
84. Steidler L., Hans W., Schotte L., Neirynck S., Obermeier F., Falk W., Fiers W., Remaut E.: Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science, 289, 1352-1355 (2000)
85. Su G.F., Brahmbhatt H.N., Wehland J., Rohde M., Timmis K.N.: Construction of stable LamB-Shiga toxin B subunit hybrids: analysis of expression in Salmonella typhimurium aroA strains and stimulation of B subunit-specific mucosal and serum antibody responses. Infect. Immun. 60, 3345-3359 (1992)
86. Tacket C.O., Kelly S.M., Schodel F., Losonsky G., Nataro J.P., Edelman R., Levine M.M., Curtiss R., 3rd: Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system. Infect. Immun. 65, 3381-3385 (1997)
87. Tacket C.O., Mason H.S., Losonsky G., Clements J.D., Levine M.M., Arntzen C.J.: Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nat. Med. 4, 607-609 (1998)
88. Tacket C.O., Mason H.S., Losonsky G., Estes M.K., Levine M.M., Arntzen C.J.: Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes. J. Infect. Dis. 182, 302-305 (2000)
89. Takahashi I., Marinaro M., Kiyono H., Jackson R.J., Nakagawa I., Fujihashi K., Hamada S., Clements J.D., Bost K.L., McGhee J.R.: Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J. Infect. Dis. 173, 627-635 (1996)
90. Thanavala Y., Yang Y.F., Lyons P., Mason H.S., Arntzen C.: Immunogenicity of transgenic plant-derived hepatitis B surface antigen. Proc. Natl. Acad. Sci. USA, 92, 3358-3361 (1995)
91. Tijhaar E.J., Siebehnk K.H., Karlas J.A., Burger M.C., Mooi F.R., Osterhaus A.D.: Induction of feline immuno-deficiency virus specific antibodies in cats with an attenuated Salmonella strain expressing the Gag protein. Vaccine, 15, 587-596 (1997)
92. Truitt R.L., Hanke C., Radke J., Mueller R., Barbieri J.T.: Glycosphingolipids as novel targets for T-cell suppression by the B subunit of recombinant heat-labile enterotoxin. Infect. Immun. 66, 1299-1308 (1998)
93. van Ginkel F.W., Jackson R., Yuki Y., McGhee J.: Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J. Immunol. 165, 4778-4782 (2000)
94. Verthelyi D., Zeuner R.A.: Differential signaling by CpG DNA in DCs and B cells: not just TLR9. Trends Immunol. 24, 519-522 (2003)
95. Verweij W.R., de Haan L., Holtrop M., Agsteribbe E., Brands R., van Scharrenburg G.J., Wilschut J.: Mucosal immunoadjuvant activity of recombinant Escherichia coli heat-labile enterotoxin and its B subunit: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen. Vaccine, 16, 2069-2076 (1998)
96. Wagner H.: Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity. Curr. Opin. Microbiol. 5, 62-69 (2002)
97. Woolhouse M.E.: Population biology of emerging and reemerging pathogens. Trends Microbiol. 10, S3-7 (2002)
98. Wu H.Y., Russell M.W.: Induction of mucosal and systemic immune responses by intranasal immunization using recombinant cholera toxin B subunit as an adjuvant. Vaccine, 16, 286-292 (1998)
99. Wu S., Pascual D.W., Lewis G.K., Hone D.M.: Induction of mucosal and systemic responses against human immunodeficiency virus type 1 glycoprotein 120 in mice after oral immunization with a single dose of a Salmonella-HIV vector. AIDS Res. Hum. Retroviruses, 13, 1187-1194 (1997)
100. Yu J., Langridge W.H.: A plant-based multicomponent vaccine protects mice from enteric diseases. Nat. Biotechnol. 19, 548-552 (2001)